Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Finally, we arrived to the day we have been waiting for since November 2023. I want to highlight 1 fact:
"Since all patient data will be included in the final locked database, we will remain blinded and will announce the comprehensive results of the full trial, including Stage II results, rather than proceeding with the original plan of announcing top line results for Stage I only.
So many patients chose to continue the treatment, that they couldn't have a intermediate data readout in november last year. SUPER BULLISH on those results. Don't forget that the primary endpoint are Patient Reported Outcomes (PRO's) GLTA
Well now we wait. Hopefully we wake up to good news.
with the SMALL number of shares outstanding, one would think good news could
lead to some upside movement.
But at the same time, those SHORT and holding onto their positions could put a damper
on things in a hurry IF there aren't a lot paying attention to the news
all going to hinge on what they say, how loud they say it, and IF the market is again, paying attention.
Its tried to move higher 2x today and got dragged down in response..
pick your reason.. See what it does into the close..
JAGX > IS A GREAT $$$$$ OPPORTUNITY.
Nice seeing the recent upside moves for the Jaguar.
Are expecting this to rockets assume postiviee results "?
Tomorrow morning is going to be one of those 'binary' events in the
baby bio tech world isn't it.
Tommy its not HYPE, its called a PH 3 data release
IF you have been investing in bios, you should know that
clinical trials try to 'prove' something. And if they are successful,
likely to lead to an increase in revenues (note, not every development
is actually a revenue generator, ask Sony and their BETA development vs
VHS)
So out of curiosity, why are you claiming this is all 'hype'??
The PH 3 data will answer the first question of, does it work or not.
The next few questions if the data is good, will be, will it 'sell' and how
much (volume of sales), and for 'how much' (profits). While I dislike reverse
splits when they are done at the wrong time, one positive is, the severely reduced
share count can make things a bit more exciting (less shares to spread any profits against)
going forward..
and a disclaimer: yes, I held no shares when the r/split occurred, and didn't start buying
until the share price had fallen below $5/sh.
Here's hoping the PH 3 data is good, especially for those that could benefit from its development
They already have a life changing event in progress, and anything that makes it easier to deal with,
you have to hope for their sake, it happens
Hey TOMMY... Not my fault you need $1280 to 'break even'..
Just a recommendation, but if you are honest with this comment, you
might want to re-evaluate your investment strategy. Seriously.
As for the pumping, not just posting what the CHART was showing,
and its looking prettier than it was when I posted the comment.
Going to be interesting to see if the FOMO folks show up on Monday
to see if they can scalp some fast gains on Tuesday.
Date and time set:
https://www.accesswire.com/889979/jaguar-health-to-report-phase-3-ontarget-trial-results-for-its-cancer-supportive-care-drug-crofelemer-on-july-23rd-and-hold-investor-webcast-that-morning
"Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on Tuesday, July 23, 2024 at 8:30 AM Eastern to review results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. A press release announcing the results will be issued that morning, prior to the webcast. The webcast will provide updates on Jaguar's advancing cancer supportive care portfolio and include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis. "
I've just re-entered this morning, at ~$4, hoping for the best....
Only one's laughing at the end, will be the ones that timed this better than you did. As is often the case in biotech stocks. The results will be good, and you know that. That's the reason you invested in the first place.
You are just frustrated that even on good results, you won't be able to break-even. Which I completely understand, but trading emotionally like this, is not a good option
Anyone buying into this hype..
Is an absolute idiot. Why not give back $13 million dollars...on your salary. I feel so sorry for anyone buying into this garbage. Results coming tomorrow ? Hahahahaha
Are you fuc king serious ? You pump garbage POS ! I need $1280 a share just to break even. I guess I bought in too early..They will continue raping shareholders at every turn. Obviously you're working for the company you piece of s***
BUY signals are intact, but its still facing a little bit of negative sentiment..
Share price is just above the MOVING Ave line, and its rising. Now to see if it can
help carry the share price 'higher'.. (smile)
Asked to 'lend' my shares to the shorts..
Just got a notice from Schwab asking if I wanted to be paid to 'lend' my shares for short selling.
The borrow rate listed was 77%.. Subject to 'change' of course, but sounds like someone wants some
shares to short 'really' bad to willing to pay that to get their hands on some
Trend need to hear your 2 cents on this again
It looks like FOMO will be building for next TWO weeks.
This is easy money to $8 before the P3
If Results are Good-We could have news this week
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025
Napo currently holds approximately 152 patents and approximately 43 patents pending.
https://jaguarhealth.gcs-web.com/news-releases/news-release-details/issuance-new-european-australian-patents-bolster-ip-protection
You will get it in less than 11 trading days.
This one is not for rookies like you
Wondering if they have any results?? Or even if it’s positive. Incompetent management
brains lol .... hope some day you get some brains your daddy will be happy
look at the pps idiot
Dah...they reversed split ..of course their off the non compliance list. Until they go under a dollar again for the umpteenth time and reverse split again..geez ..what don't you get ? Endless cycle of destruction.
Why are you a jackass harassing folks with their investing??
Good to know. Thanks for the details.
It appears the company is off the noncompliance list. Of course we don’t know the details, but looking at the circumstances and timeframes involved in terms of the duration it took to satisfy Nasdaq and the projected timing of the P3 results one can reasonably infer that the RS was likely necessary to ensure compliance was regained by Aug 13 and perhaps more importantly prior to the announcement of P3 (hopefully to clear the way for institutional investors).
REGAINED COMPLIANCE: Press Release expected today. Source: https://listingcenter.nasdaq.com/noncompliantcompanylist.aspx
Trying to fight back over its Moving Average line
When a share price falls below the MA line, I watch for the 'challenge' that has to take
place to take the pressure off the price. Last Friday, the price pushed up against the MA line
That was good to see, but yesterday/today whats quite normal occurred. The MA line 'won' the
first skirmish.
But in a sign that there is 'demand' for the shares, there will be another challenge made and maybe
Jagx doesn't win the next one either. But what I look for is for when it finally breaks thru, for what tends to
come next. And thats that as the MA line shifts from a negative slope towards neutral and then tilts slightly positive?
Will it start to help 'LIFT' the share price up. Thats when these CORRECTION PHASES gets to be fun.
Glug glug glug ..the Titanic is gaining water. Wait till .75 cents 🙈
Agree. It seems to me now is a time to own. Time will tell.
Agree that the CEOs focus is on the companys success vs keeping the retailers happy.
The only caveat is a friendly reminder that because the company needs to do what they need to do
is that there is a time to own, and a time to step aside.
These damn nearly 5 year cycles to get something approved can be death traps if the company
needs to do secondaries and reverse splits. For me, in the early stages, i take what it gives and
if they announce splits/secondaries? Its probably a pretty good idea to step aside and look to reload
afterwards IF THERE is NO GOOD NEWS associated with the 'event' to help draw the markets interest
to help hold the share price up.
Especially in markets like the one we are in now where money flow seems to be directed to big names,
and those with potential are being ignored, even if they give the market a good reason to want some..
In my opinion we are seeing a retail shakeout driven by fear tactics that are not entirely without grounds given the history of the company’s dilutive actions. However, it seems to me that what people fail to realize is all those maneuvers were likely taken in an effort to get the company to where things appear to be headed in a month — the release of Phase 3 results. I seriously doubt the CEO cares about retail or ever has. Instead she likely cares about her life’s work the culmination of which seems to be almost here.
There is a lot of noise. Of course I don’t know what will happen, but I think this is an opportunity for patient retail investors who refuse to be scared off.
Going down?? Oh boy. Shorts borrowed ALL AVAILABLE shares , 35 000 !!! , at a cost to borrow rate of 253% !!!
And all you guys managed was a small 3% drop on a bad market day? It's pathetic, and shorts are losing EVERY DAY.
While BULLS are waiting FOR FREE.
Except Peter doesn't have the brains to explain us which shares they are going to sell. They didn't ask for extra shares on the shareholders meeting. And the only shares left are those of the 75 million MIXED share offering. Which can partly be used to issue more shares, but are much more warrants, or preferred shares; etcetera... To attract another kind of investors.
He is just too stupid to explain us. Don't mind this guy
Is this your FIRST biotech development stock or something??
Is dilution something NEW to you cause its quite common for
a baby bio thats essentially just getting started.
Has to be factored in.
i did .... dilution pig
You still didn't answer the question. Why be a jackass about it...
Sure its likely to need to do an offering to raise cash down the road. That happens
very frequently doesn't it to baby bios that need to go thru the FDA 'one size fits all' clinical trial process.
No need to be an ass about it.
Take your gains if you can get em and be grateful for the opportunity.
watch and learn this turd only sels shares
peterus: why do some like yourself have to be a JACKASS?
Just curious..
bla bla bla but your dilution turd is going down again idiot
Reporting all the 'proposals' passed. Highlighted again they expect the PH 3 results by 7/23...
https://finance.yahoo.com/news/jaguar-health-reports-approval-proposals-201500118.html
Chart is looking quite nice. BUY signal has confirmed.
IF the chart isn't wrecked by some nasty unexpected surprise, am expecting to see the share price
at least hold its ground.
Followers
|
136
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6959
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Pipeline: https://jaguar.health/pipeline/
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |